DP
Diadema Partners Portfolio holdings
AUM
$161M
This Quarter Return
+0.4%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$161M
AUM Growth
+$161M
(+29%)
Cap. Flow
+$39.8M
Cap. Flow
% of AUM
24.76%
Top 10 Holdings %
Top 10 Hldgs %
70.2%
Holding
94
New
17
Increased
16
Reduced
11
Closed
14
Top Buys
| 1 |
Soleno Therapeutics
SLNO
|
$16M |
| 2 |
Amgen
AMGN
|
$14.5M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$7.7M |
| 4 |
TG Therapeutics
TGTX
|
$5.89M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$4.45M |
Top Sells
| 1 |
Regeneron Pharmaceuticals
REGN
|
$12.7M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$3.54M |
| 3 |
Eli Lilly
LLY
|
$3.5M |
| 4 |
argenx
ARGX
|
$3.48M |
| 5 |
Rhythm Pharmaceuticals
RYTM
|
$2.65M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Reviva Pharmaceuticals
RVPH
$30.8M
| $1.04M | 0.32% |
2,735,457
+2,084,734
| +320% | +$794K |
|
27
MindMed
MNMD
$676M
| $1.03M | 0.31% |
+158,536
| New | +$1.03M |
|
28
Trevi Therapeutics
TRVI
$883M
| $1.02M | 0.31% |
185,830
+5,830
| +3% | +$31.9K |
|
29
Terns Pharmaceuticals
TERN
$609M
| $969K | 0.3% |
259,852
+203,754
| +363% | +$760K |
|
30
89bio
ETNB
$1.34B
| $966K | 0.29% |
98,382
-133,054
| -57% | -$1.31M |
|
|
CLYM
31
Climb Bio, Inc. Common Stock
CLYM
$151M
| $871K | 0.27% |
702,135
+32,332
| +5% | +$40.1K |
|
32
scPharmaceuticals
SCPH
$295M
| $829K | 0.25% |
+217,623
| New | +$829K |
|
33
VistaGen Therapeutics
VTGN
$102M
| $808K | 0.25% |
403,922
-162,053
| -29% | -$324K |
|
34
Arvinas
ARVN
$568M
| $710K | 0.22% |
+96,455
| New | +$710K |
|
35
Apogee Therapeutics
APGE
$2.17B
| $459K | 0.14% |
10,572
-29,428
| -74% | -$1.28M |
|
36
Phathom Pharmaceuticals
PHAT
$864M
| $386K | 0.12% |
+40,294
| New | +$386K |
|
37
Nuvalent
NUVL
$5.54B
| $382K | 0.12% |
+5,000
| New | +$382K |
|
38
Alector
ALEC
$262M
| $372K | 0.11% |
266,023
-190,523
| -42% | -$267K |
|
39
ProQR Therapeutics
PRQR
$237M
| $322K | 0.1% |
157,694
-50,000
| -24% | -$102K |
|
40
Replimune Group
REPL
$461M
| $302K | 0.09% |
32,483
-42,047
| -56% | -$391K |
|
41
Eledon Pharmaceuticals
ELDN
$155M
| $175K | 0.05% |
64,613
| – | – |
|
42
Relay Therapeutics
RLAY
$619M
| $151K | 0.05% |
43,616
-382,730
| -90% | -$1.32M |
|
|
ELEV
43
DELISTED
Elevation Oncology
ELEV
| $133K | 0.04% |
+362,935
| New | +$133K |
|
|
PRTC
44
PureTech Health
PRTC
$413M
| $126K | 0.04% |
+7,324
| New | +$126K |
|
45
Summit Therapeutics
SMMT
$17.7B
| $19.8K | 0.01% |
+932
| New | +$19.8K |
|
46
Zai Lab
ZLAB
$3.68B
| $13.2K | ﹤0.01% |
+3,785
| New | +$13.2K |
|
47
Acadia Pharmaceuticals
ACAD
$4.38B
| – | – |
0
| – | – |
|
48
Agios Pharmaceuticals
AGIO
$2.28B
| – | – |
0
| – | – |
|
|
49
Alnylam Pharmaceuticals
ALNY
$58.5B
| – | – |
-13,115
| Closed | -$3.54M |
|
50
Altimmune
ALT
$331M
| – | – |
0
| – | – |
|